Q5106 Insurance Policy Changes

HCPCS Q5106 is officially defined as "Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units." HCPCS Q5106 is referenced in 5 tracked payer policy changes from Florida Blue, Highmark, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q5106 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.